Faisal Khurshid
Stock Analyst at Leerink Partners
(0.75)
# 3,659
Out of 4,827 analysts
19
Total ratings
28.57%
Success rate
-16.11%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.70 | +42.19% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $14.65 | +207.17% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $9.68 | +65.29% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $0.98 | +307.50% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.44 | +38.89% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $3.32 | +382.65% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $31.58 | +89.99% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $70.53 | +13.43% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $1.26 | +1,090.48% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $6.50 | +7.69% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $15.89 | +183.20% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $25.53 | -5.99% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.26 | +455.56% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $4.63 | +72.79% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $1.02 | +392.61% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $6.78 | +62.21% | 1 | Mar 21, 2023 |
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.70
Upside: +42.19%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $14.65
Upside: +207.17%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $9.68
Upside: +65.29%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $0.98
Upside: +307.50%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.44
Upside: +38.89%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $3.32
Upside: +382.65%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $31.58
Upside: +89.99%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $70.53
Upside: +13.43%
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.26
Upside: +1,090.48%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $6.50
Upside: +7.69%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $15.89
Upside: +183.20%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $25.53
Upside: -5.99%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.26
Upside: +455.56%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $4.63
Upside: +72.79%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $1.02
Upside: +392.61%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $6.78
Upside: +62.21%